Kornimate/medical-research-clean huggingface dataset:
quality of life, sleep, and biomarkers in people with hiv/aids

Conditions: HIV/AIDS and Infections; Disorder Sleep; Lipodystrophy

Summary: aim: evaluate the influence of exercise, in different times, on quality of life, sleep and clinical parameters in people living with hiv/aids (plha). methods: intervention study, prospective.

aim: evaluate the influence of exercise, in different times, on quality of life, sleep and clinical parameters in people living with hiv/aids (plha). methods: intervention study, prospective, a cohort with 17 plha participants of the exercise program, higher than 18 years, under antiretroviral therapy with cd4+ ≥ 350/mm3. research ethical committee of the institution approved the study and the participants sign the informed consent and informed. all subjects underwent an exercise program in conformity to american college of sports medicine, 3 times per week during 40 minutes. were evaluated the quality of life (qol) with the quality of life - hat - qol and the sleep quality (sq) with the pittsburg questionnaire. the subjects were evaluated before the start of exercise program and in three times: short-term (2 to 4 months), medium-term (between 5 and 17 months) and long-term (between 18 to 25 months).

Eligibility criteria:
inclusion criteria: * must have age ≥ 18 years old; * diagnosis of hiv/aids; * use of antiretroviral therapy; * must have lymphocyte t cd4+ cell count ≥ 350 cel/mm3 * must have physical fitness by the assistant physician. exclusion criteria: * pregnancy; * severe hearing deficiency.

Keywords: exercise therapy; sleep; ; immune markers; hiv
study of the quality of sleep of parents of premature children compared to parents of full-term children

Conditions: Prematurity; Parenting; Sleep Deprivation

Summary: this study evaluate the incidence of sleep disorders in parents of premature children hospitalized in unit care of neonatalogy or intensive unit care of neonatalogy, compared to parents of full-term child in maternity.


Eligibility criteria:
inclusion criteria: * couple of parents of children born before term (between 25 and 36 weeks) and hospitalized at the chru de brest. * parents of healthy full-term children born at brest chru (\> 37 weeks) without neonatal hospitalization. * having formulated their agreement exclusion criteria: * parents whose child died in the neonatal period. * couple whose one parents are minors at the birth of the child. * parents of children with malformation and /or genetic anomaly. * parents with known addiction, depressive syndrome or known psychiatric condition before birth. * single parent family. * non-french speaking parents. * refusal of participation of one of the parents.
comparison of the accuracy of non-invasive hemoglobin measurement (sphb) and vena cava inferior ultrasound

Conditions: Blood Donors, Traumatic Blood Loss

Summary: the aim of this work is determine the more successful noninvasive method by comparison of two noninvasive methods ( ivc ultrasound - noninvasive hemoglobin measurement (sphb)) that used in the detection of patients with blood loss. the works were completed in 6 months. the study was conducted at the blood donation center and in emergency department. vital parameters were measured and recorded before making the voluntary blood donation. following masimo brand portable device fingers sphb value was measured.then ivc diameter of patients in the supine position were measured using ultrasonography. then he left to donors return in routine blood donation programme. a unit (500ml) of blood were drawn from each donor. after the blood donation process measured and recorded the vital signs again. sphb was measured noninvasively from finger again. following these measurements were recorded again by measuring the diameter of ivc.


Eligibility criteria:
inclusion criteria: * who have volunteered to donate blood * older than 18 years * both sexes exclusion criteria: * known tricuspid valve regurgitation and right heart failure * oral intake or the fluid loss (diarrhea and vomiting-urination) between the two measurements during the blood donation * inappropriate echogenicity for vena cava inferior diameter measurement

Keywords: blood donors blood donation traumatic blood loss trauma
sex difference of coronary microvascular dysfunction in patients with non-obstructive coronary artery disease

Conditions: Microvascular Angina

Summary: sex difference of coronary microvascular dysfunction evaluated by coronary flow reserve will be assessed in patients with non-obstructive coronary artery disease

the investigators will select consecutive patients who experienced chest pain but had no significant coronary artery stenosis (\<50% stenosis). coronary microvascular function will be evaluated by adenosine stress echocardiography. coronary blood flow velocities will be measured at 1, 2, and 3 min after adenosine infusion. sex difference of coronary microvascular dysfunction evaluated by coronary flow reserve will be assessed.

Eligibility criteria:
inclusion criteria: * typical/atypical chest pain or ischemic symptoms including dyspnea * no significant coronary artery stenosis (\<50% stenosis) in coronary angiography or computed tomography exclusion criteria: * ≥ moderate valvular heart disease * congenital heart disease * chronic renal failure (estimated glomerular filtration rate \<30 ml/min/1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis * asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension * receiving anticancer drugs * vasculitis associated with autoimmune diseases * atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, wolff-parkinson-white (wpw) patients
nimotuzumab concurrent with chemoradiotherapy for patients with unresectable esophageal squamous cell carcinoma

Conditions: Esophageal Cancer; Nimotuzumab; Chemoradiotherapy; Chemotherapy; Immunotherapy

Summary: patients diagnosed with locally advanced esophageal squamous cell carcinoma (escc) who failed to induction chemo(immuno)therapy had poor prognosis. radiotherpy was an important and effective treatment in treating escc. the present study is a one-arm trial that seeks to evaluate the efficacy in patients with unresectable escc. the study objectives include r0 resection rate, complete pathological response and treatment toxicity, etc. nimotuzumab is a recombinant humanized monoclonal antibody against egfr. its efficacy and safety in patients with esophageal cancer have been confirmed by many studies. the current prospective phase ii study aimed to evaluate the efficacy and safety of a combination regimen comprising chemotherapy with nimotuzumab and s-1 and concurrent radiotherapy for patients who are not sensitive to induction chemo(immuno)therapy.


Eligibility criteria:
inclusion criteria: * histologically confirmed esophageal squamous cell carcinoma. tumor response was evaluated as stable or locoregionally progresive disease or assessed by surgeons being unresectable (without distant metastasis) after induction chemo(immuno)therapy. * cycles of induction chemo(immuno)therapy was 2-4. * kps score ≥70. * main organs and bone marrow function are normal: routine blood tests: hemoglobin (hb) ≥100g/l ; absolute neutrophil count (neut)≥1.5×109/l; platelets (plt) ≥100×109/l; white blood cell (wbc)≥3.5×109/l,biochemical examination: alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤1.5×unl; serum total bilirubin (tbil) ≤1.5×unl; serum creatinine ( cr) 1.0×1.5unl, and bun≤1.0×unl; exclusion criteria: * those combined with other primary malignant tumors other than esophageal cancer (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix); * at the time of diagnosis, there were distant and hematogenous metastases beyond the supraclavicular lymph node region, including retroperitoneal multiple lymph node metastasis, bone metastasis, brain metastasis, lung metastasis, liver metastasis, malignant pleural effusion and ascites * there are active infections, such as active tuberculosis and hepatitis * there are contraindications to targeted therapy.
web-based intervention designed to educate and improve adherence through learning to use continuous glucose monitoring

Conditions: Type 1 Diabetes Mellitus; Continuous Glucose Monitor

Summary: the goal of this pilot study is to produce a high-quality, theory-driven, therapeutic, web-based intervention that provides extended training and peer support to adolescents and young adults with type 1 diabetes who are newly implementing cgm. overall, this web-based intervention represents an efficient way to bring together professionally-supported cgm educational materials and social support to overcome known barriers and address factors associated with inconsistent cgm use.


Eligibility criteria:
inclusion criteria: 1. ability to read and speak english 2. diagnosed with type 1 diabetes (t1d) for \> 3 months before consent is obtained 3. aged \>15 years and \<24 years at time of enrollment 4. must have access to a smartphone, tablet or laptop/desktop computer with high speed internet access and speaker 5. must be using/initiating a dexcom cgm exclusion criteria: 1. cognitive or learning disability (e.g., inability to read) that would preclude their ability to comply with the study protocol 2. significant medical comorbidity in the adolescent or young adult that could, in the opinion of the pi, affect subject's capacity to follow study protocol 3. previous use of a cgm within the last 3 months 4. unwilling or unlikely to return to clinic for a follow-up hba1c test 5. unwillingness to accept randomization
contingency management for opioid and stimulant use disorders in primary care

Conditions: Opioid Use Disorder; Stimulant Use Disorder

Summary: contingency management (cm) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting. when applied to the treatment of substance use disorders, it has demonstrated efficacy in reducing the number of urine toxicology screens positive for illicit substances and increased engagement in treatment programs. however, there is a need to translate cm treatment to primary care settings. this study will implement and assess a cm program for patients with opioid use disorder, with or without comorbid stimulant use disorder, initiating outpatient addiction medicine services at a family medicine residency clinic. eligible patients will earn monetary incentives for attending addiction medicine appointments and abstaining from substances during outpatient treatment. data gathered from this pilot program will be used to improve patient outcomes, treatment, and retention for persons receiving medications for opioid use disorder (mouds) in a primary care setting.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * diagnosis of opioid use disorder and/or stimulant use disorder * recently initiated medications for opioid use disorder (mouds) at broadway family medicine (bfm), within 2 weeks of recruitment * have an active prescription for buprenorphine-naloxone (suboxone) exclusion criteria: * prescription for an amphetamine would exclude patients from the abstinence-based cm, but they could participate in the attendance-only cm. * dementia, development disabilities, or cognitive functioning that is too low to participate in study measures, as determined by chart review and consultation with overseeing physician.

Keywords: opioid use disorder stimulant use disorder contingency management primary care addiction medicine buprenorphine
investigating the safety and effect of overnight orthokeratology and its influencing factors

Conditions: Myopia

Summary: to investigate the safety and effect of overnight orthokeratology and its influencing factors in china

patients who were successfully prescribed with orthokeratology lenses in eye center of the second affiliated hospital of zhejiang university school of medicine were enrolled in the study. our study used two different methods to collect data. for complications and effect of orthokeratology information, data were collected by a retrospective survey. a questionnaire was used to collect influencing factors of safety and effect of orthokeratology.

Eligibility criteria:
inclusion criteria: * patients who were successfully prescribed with ortho-k lenses in eye center of the second affiliated hospital of zhejiang university school of medicine exclusion criteria: * patients who have ceased wearing orthokeratology or who were using other methods of myopia control

Keywords: orthokeratology myopia control
evaluating sublingual dexmedetomidine for moderate to severe agitation in inpatients with schizophrenia or bipolar disorder

Conditions: Schizophrenia Agitation; Schizo Affective Disorder; Bipolar Disorder; Dexmedetomidine

Summary: an open-label, randomized, active control inpatient trial to evaluate the efficacy and tolerability of sublingual dexmedetomidine for the treatment of agitation in inpatients with schizophrenia or bipolar disorder as measured by the positive and negative syndrome scale - excited component (panss-ec) and agitation-calmness evaluation scale (aces). lorazepam will serve as the active control.

this is an open-label, randomized control trial where patients (n=32) with schizophrenia or bipolar disorder are randomized to receive either sublingual dexmedetomidine or oral lorazepam monotherapy for the treatment of episodic agitation. for moderate agitation (panss-ec score ≥14 and \<20), patients will receive either sublingual dexmedetomidine 120mcg or oral lorazepam 2mg. for severe agitation (panss-ec ≥20), patients will receive either sublingual dexmedetomidine 180mcg or oral lorazepam 2mg. the panss-ec and aces will be evaluated at baseline and after 15, 30, 60, and 120 minutes.

Eligibility criteria:
inclusion criteria: * the participant is an adult between the ages of 18-55 at the time of study participation * hospitalized on an inpatient unit at episcopal hospital * meet the dsm-5 criteria for schizophrenia, schizoaffective disorder, or bipolar disorder, as determined by routine clinical assessment conducted upon admission. * are able to understand and read english * are able to provide informed consent * experiencing a moderate (panss-ec score ≥14 and \<20) or severe (panss-ec score ≥20) episode of agitation exclusion criteria: * women who are pregnant or breastfeeding * prisoners * participant has an allergy to dexmedetomidine or lorazepam * participant has mild, moderate or severe hepatic impairment * participant has active pulmonary disease and is receiving treatment (oxygen, inhalers) * individual is currently prescribed scheduled benzodiazepines or methadone * participant history of qtc ≥ 500 msec or a history of arrythmia * participant recent (within the last 2 days) fall, syncope (passing out), feeling lightheaded, or pulse \<50. * individual has a history of hypokalemia or hypomagnesemia within the past 2 years? * participant is receiving high-risk medications, including: 1. methadone 2. midazolam 3. opioids 4. high risk medications associated with the qt interval prolongation (sertindole, chlorpromazine, ziprasidone), (amiodarone, iboga, quinine, arsenic, ibutilide, selpercatinib, ivosidenib, bedaquiline, lenvatinib, sotalol, levoketoconazole, cisapride, vendetanib, mobocertinib, disopyramide, papaverine)

Keywords: agitation schizophrenia schizoaffective disorder bipolar disorder
multiparametric assessment of maternal vascular function in the prediction of hypertensive disorders of pregnancy

Conditions: Preeclampsia; Hypertensive Disorder of Pregnancy

Summary: the present study is a single-centre prospective study that will enrol pregnant women during their first trimester of pregnancy (11+0 - 13+6 weeks of gestation). during pregnancy, women will undergo standard clinical evaluation and management. during the two study visits (enrollment and 24+0 - 27+6 weeks of gestation) the investigators will perform arterial tonometry (pulsepen) and in vivo darkfield microscopy (glycocheck) to evaluate endothelial and vascular function. a urine sample and a blood sample for specific study analyses on metabolic profile, endothelial and angiogenic markers will be collected. pregnancy outcomes will be collected at delivery and five years after delivery all the participants will be interview to collect long-term cardiovascular outcomes. serum endothelial and angiogenic markers will be evaluated only in participants who will develop hypertensive disorders of pregnancy and in an equal number of controls matched for age and body mass index at the time of conception.

primary aim: to determine the role of the combination of arterial tonometry and endothelial glycocalyx measurement in predicting the risk of developing hypertensive disorders in pregnancy. secondary aims: * to determine the association between circulating markers of angiogenesis and endothelial dysfunction (ang-1, ang-2, et-1, icam-1 and vcam-1) and the development of hypertensive disorders of pregnancy. * to define the trends of serum uric acid, lipids and xanthine oxidase activity in normotensive and hypertensive pregnancies. * to determine the ability of the combination of arterial tonometry and endothelial glycocalyx measurement, performed in the two study visits during pregnancy, in predicting the risk of long-term maternal cardiovascular disease.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * single pregnancy * no previous pregnancies lasting more than 12 weeks * participant willing and able to give informed consent for participation in the study exclusion criteria: * intermediate-high risk of genetic abnormalities and/or need to perform invasive tests (amniocentesis, villocentesis) * history of solid organ or hematopoietic stem cell transplantation * chronic renal failure (egfr≤45ml/min/1.73m2) * chronic treatment with antihypertensive drugs and/or xanthine oxidase (xo) inhibitors

Keywords: preeclampsia hypertensive disorders of pregnancy hypertension obstetric medicine cardio-obstetrics cardiovascular outcomes pregnancy complications arterial stiffness endothelial glycocalyx endothelial dysfunction uric acid oxidative stress xanthine oxidase lipids
quality of life after cervical ripening

Conditions: Delivery

Summary: women's experience of childbirth differs with type of labor, mode of delivery and parity. induction of labor (iol) is associated with lower satisfaction of women than spontaneous labor. a nigerian study of 252 women with induced labor, irrespective of parity and device used for iol and a french cohort study of 3042 women with iol have been published. theses latter identified several determinants of maternal dissatisfaction. however, no published study has reported the assessment of quality of life of women at long term after cervical ripening according to the device required for cervical ripening. the aim of this study is to characterize the quality of life of women after cervical ripening according to parity and device required, and to assess possible factors associated with this quality of life at long-term after delivery.


Eligibility criteria:
inclusion criteria: - woman who experienced at least one method of cervical ripening in our hospital exclusion criteria: - patient's refusal
ct in calcified coronary arteries with photon counting detector

Conditions: Coronary Stenosis; Calcific Coronary Arteriosclerosis

Summary: coronary ct angiography is challenging in patients with more than mildly calcified coronary vessels, because of calcium artefacts that prevents evaluation of the lumen. the purpose of the cct-pcd-1-study is to evaluate the diagnostic accuracy and image quality in coronary ct angiography using a commercially available ct system equipped with a photon counting detector technology. patients referred for cardiac ct and conventional coronary angiography as part of routine preoperative evaluation before transcatheter aortic valve implantation (tavi) will be asked for inclusion in the study. this group of patients has generally a coronary artery calcium burden and perform cardiac ct and coronary angiography as part of routine care. the diagnostic accuracy concerning significant coronary artery stenosis on the preoperative ct will be evaluated with the conventional coronary angiography as reference. also, ct examination image quality will be evaluated.


Eligibility criteria:
inclusion criteria: * patients referred for cardiac ct and conventional coronary angiography as part of routine preoperative evaluation. exclusion criteria: * \<65 years old. * heart arrhythmia. * heart rate \>90/min with contraindication against beta blockers. * not capable of giving informed consent * egfr \<30 ml/min/1.73m2

Keywords: cardiac computed tomography photon counting detector
the safety, tolerability and pharmacokinetics study of ray1216 in healthy adult participants

Conditions: COVID-19 (Coronavirus Disease 2019)

Summary: this is double-blind,randomized, single and multiple dose trial to evaluate the pharmacokinetics(pk), safety, tolerability and drug-drug interaction of ray1216, and the effect of food on ray1216 pharmacokinetics.


Eligibility criteria:
inclusion criteria: 1. signature of a dated informed consent form (icf) indicating that the subject has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment. 2. subjects must be willing and able to adhere to the visit schedule and protocol requirements and be available to complete the study. 3. subjects (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product. 4. males and female subjects between 18-50 years (both inclusive). body weight is no less than 50 kg in males and no less than 45 kg in females. body mass index (bmi) 18≤bmi≤28 kg/m2; bmi is determined by the following equation: bmi = weight/height2 (kg/m2). 5. physical condition and vital signs: normal or abnormality has no clinical significance. exclusion criteria: 1. known hypersensitivity and/or allergy to some drugs and food, especially for the composition that is similar to the investigative product; 2. the average daily smoking are more than 5 cigarettes within 3 months prior to screening. 3. known history of drug or alcohol abuse.(defined as consumption of 14 units of alcohol per week: 1 unit = 285 ml of beer; or the equivalent of 25 ml of spirit, or 100 ml of wine ) 4. subjects who donated blood or bleeding profusely (\> 400 ml) in the 3 months preceding study screening. 5. dysphagia or any medical history in gastrointestinal that interferes with the absorption of drugs, include a history of frequent nausea or vomit causes by any etiology. 6. history or presence of any disease or condition known to increase the risk of bleeding , eg. acute gastritis, duodenal ulcer, etc. 7. participated in another clinical research study and received any investigational products within 3 months prior to dosing. 8. history of having any special food (including dragon fruit, mango, grapefruit, etc.), strenuous exercises, or other factors may interfere with the absorption, distribution, metabolism, or excretion of drug within 7 days prior to screening. 9. inability to consume the food provided in the study ( a high fat diet).this requirement only applies to subjects under fed condition. 10. presence of clinically significant abnormalities in ecg or qtcf\>450ms 11. subjects who may not complete the study for other reasons or should not be included in the study in the opinion of the investigator.